Swiss Insurance Stock News

Georg Fischer AG has released its half-year 2026 results, reporting sales of CHF 1,584 million, revenue of CHF 1,615 million and a net loss of CHF 77 million, compared with a profit a year earlier. The swing from net income to a loss, alongside earnings per share moving from profit to loss, marks a clear reversal in the company’s recent financial performance. We’ll now examine how this shift from profit to loss in the latest half-year results could influence Georg Fischer’s investment...

EFG International earnings event and why it matters EFG International (SWX:EFGN) has drawn investor attention after reporting half year 2026 net income of CHF 184.6 million, down from CHF 221.2 million a year earlier, a material update for assessing the stock. See our latest analysis for EFG International. EFG International's share price has risen 7.88% over the past month and 4.51% over the past quarter, yet is still down 8.96% year to date. Longer term total shareholder returns of 16.41%...

Sensirion Holding (SWX:SENS) has just expanded its product line with the SFM3505-300 series flow sensors, targeting applications such as mechanical ventilation and gas mixing, alongside a fresh evaluation kit for indoor air quality gas sensors. See our latest analysis for Sensirion Holding. The back to back product launches appear to have coincided with a sharp shift in sentiment, with Sensirion Holding’s share price up 7.65% over one day but down 10.48% over 30 days. The year to date share...

The European market has recently experienced volatility, with the pan-European STOXX Europe 600 Index ending a week of fluctuations broadly unchanged. Amidst this backdrop, investors are keenly analyzing corporate earnings and geopolitical tensions to identify opportunities. In such an environment, stocks that may be trading at a discount often attract attention due to their potential for value appreciation when market conditions stabilize.

Bossard Holding (SWX:BOSN) has reported solid headline numbers for H1 2026, with revenue at CHF 575.7 million and net income at CHF 53.4 million setting the tone for its latest update. The company’s revenue increased from CHF 546.7 million in H1 2025 to CHF 575.7 million in H1 2026, while net income rose from CHF 37.4 million to CHF 53.4 million over the same period. Trailing twelve month net income reached CHF 87.9 million on revenue of CHF 1.1 billion. For investors, the focus now is...

Last week, you might have seen that DKSH Holding AG ( VTX:DKSH ) released its half-yearly result to the market. The...

Swatch Group (SWX:UHR) has released its H1 2026 scorecard with trailing 12 month revenue of CHF6.4b and net income of CHF9m, set against a current share price of CHF186.35. The company has seen half year revenue move from CHF3.1b in H1 2025 to CHF3.2b in H2 2025, while net income shifted from CHF57m in H2 2024 to CHF3m and then CHF0m across the 2025 halves, leaving investors weighing weak recent profitability against analyst forecasts for 37.79% annual earnings growth. See our full analysis...

ALSO Holding (SWX:ALSN) has reported its H1 2026 numbers with revenue of about €7.1b and net income of €69.1m, while trailing twelve month revenue sits at roughly €14.7b with net income of €135.4m and EPS of €10.74. Over the past three reported half year periods, the company has seen revenue move from €5.9b in H1 2025 to €7.6b in H2 2025 and then to €7.1b in H1 2026, alongside net income shifting from €43.0m to €66.4m and then €69.1m, with EPS over the trailing twelve months at €10.74. For...

CPH Group (SWX:CPHN) has posted its H1 2026 results with trailing twelve month revenue of CHF 333.8 million and basic EPS of CHF 3.42, against a backdrop of prior-period swings in both the top and bottom line. Over recent half-year periods, revenue has moved from CHF 146.4 million in H2 2024 to CHF 175.96 million in H1 2025 and CHF 158.11 million in H2 2025, while basic EPS shifted from CHF 2.23 to CHF 2.85 and then CHF 1.04. The latest release therefore sits in the middle of a mixed trend...

Earlier this month, Novartis received traditional FDA approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression, upgrading its earlier accelerated approval that was based on proteinuria reduction. The decision is grounded in two-year Phase III data showing Fabhalta’s first-in-class oral complement inhibition meaningfully slowed estimated glomerular filtration rate decline versus placebo, reinforcing...

Mikron Holding (SWX:MIKN) opened H1 2026 with revenue of CHF 180.5 million and basic EPS of CHF 0.83, while trailing twelve month revenue stood at CHF 370.6 million with basic EPS of CHF 1.68. This provides a clear snapshot of the company’s recent earnings power. Over the last three reported halves, revenue has ranged between CHF 180.5 million and CHF 191.9 million, with basic EPS moving between CHF 0.83 and CHF 1.10. This gives investors a tight read on how the top line and EPS have tracked...

Europe’s growth story is increasingly shaped by companies tied to powerful themes like AI, automation, and digitalisation, and ASML is at the center of that conversation. Its recent Q2 update, with €9.3b in sales and 91 lithography systems sold, underlines how strongly AI-related demand is feeding into parts of the market. But a forward P/E near 50 also shows how quickly expectations can stretch. This article looks at three European Growth Stocks that are exposed to the same news backdrop as...

As geopolitical tensions and energy market volatility continue to influence the European markets, the pan-European STOXX Europe 600 Index recently experienced a decline of 1.79%. In this fluctuating environment, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to navigate these uncertain times.

Amidst geopolitical tensions and energy market volatility, the European stock market has faced challenges, with the pan-European STOXX Europe 600 Index recently experiencing a decline. Despite these uncertainties, dividend stocks remain an attractive option for investors seeking steady income streams in fluctuating markets. A strong dividend stock typically combines reliable payouts with a resilient business model that can withstand economic pressures and adapt to changing conditions.

Julius Bär Gruppe (SWX:BAER) has drawn investor attention after appointing Peter Burrill as Chief Financial Officer and Executive Board member, replacing Evie Kostakis. His start is planned for August 2026, pending regulatory clearance. See our latest analysis for Julius Bär Gruppe. At a share price of CHF74.72, Julius Bär Gruppe has seen firm momentum recently, with a 30 day share price return of 15.49% and a 90 day share price return of 20.52%, while the 1 year total shareholder return of...

As geopolitical tensions and energy market volatility weigh on European markets, the STOXX Europe 600 Index recently saw a decline, reflecting investor concerns over potential inflationary pressures and monetary policy adjustments. Amidst this backdrop, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.

As geopolitical tensions and energy market volatility weigh on European equities, the pan-European STOXX Europe 600 Index has experienced a notable decline. Amidst these market dynamics, dividend stocks can offer investors a measure of stability and income potential, making them an attractive option in uncertain times.

As geopolitical tensions and energy market volatility shape the European financial landscape, investors are closely monitoring how these factors influence inflation and monetary policy expectations. Amidst this backdrop, growth companies with high insider ownership can offer unique insights into potential resilience and strategic alignment with shareholder interests.

A “super” El Niño expected in 2026–27 could rattle food supplies, push key crop prices sharply higher, and keep inflation pressure in play for years. For investors, that kind of shock can hurt some stocks tied to food and commodities while creating openings in others that are better positioned for price spikes and volatility. This article looks at three stocks that are closely exposed to the El Niño news, with one that could benefit from the setup and two where the risks may be more...

Cembra Money Bank has recently overhauled its organisation, creating a new Sales division, a Corporate Functions division and reshaping executive roles, including appointing a Chief Sales Officer and combining the CFO and Chief Risk Officer responsibilities. By consolidating core commercial activities and elevating compliance as an independent function, the bank is signalling a stronger push for integrated customer service while preserving an emphasis on risk and control. We’ll now examine...

In July 2026, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by nearly 2% amid easing inflation concerns and stable unemployment rates. As investors navigate these conditions, growth companies with high insider ownership can present compelling opportunities due to their potential alignment of management interests with shareholders and the ability to capitalize on favorable economic developments.

As the pan-European STOXX Europe 600 Index recently advanced by 1.96%, bolstered by lower oil prices and easing inflation expectations, investor sentiment in Europe appears cautiously optimistic. In this environment, identifying undervalued stocks becomes crucial, as these opportunities may offer potential for growth when market conditions stabilize further.

Client win puts Bachem Holding in focus ImmuPharma PLC has appointed Bachem Holding (SWX:BANB) subsidiary Bachem AG to manufacture the active pharmaceutical ingredient for its Kapiglucagon program, marking a key Chemistry, Manufacturing and Controls milestone for the project. The collaboration positions Bachem Holding within the next stage of Kapiglucagon development, with work initially centered on the active ingredient before ImmuPharma selects a separate partner for drug product...

Vietnam’s latest crackdown on counterfeit luxury goods is reshaping the risk and opportunity mix for global luxury brands. With stricter enforcement on fake handbags, shoes, and accessories, some listed companies exposed to this news may see cleaner channels, changing price power, and potential shifts in supply chain costs. This article looks at three stocks from our Global Luxury Brands screener that appear positively exposed to these developments. It is intended to help you think through...